DiaMedica Therapeutics (DMAC) Accumulated Expenses (2017 - 2026)

DiaMedica Therapeutics' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 586.22% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 586.22% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 234.43% from the prior year.
• Accumulated Expenses slipped to $2.3 million in Q1 2026 per DMAC's latest filing, from $3.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.5 million in Q4 2025 and bottomed at $161000.0 in Q1 2023.
• The 5-year median for Accumulated Expenses is $1.1 million (2024), against an average of $1.5 million.
• Across the five-year window, Accumulated Expenses plunged 83.35% in 2023 and soared 1027.33% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $1.4 million in 2022, then tumbled by 43.88% to $766000.0 in 2023, then jumped by 38.38% to $1.1 million in 2024, then surged by 234.43% to $3.5 million in 2025, then sank by 33.99% to $2.3 million in 2026.
• Per Business Quant, the three latest DMAC Accumulated Expenses figures stand at $2.3 million (Q1 2026), $3.5 million (Q4 2025), and $920000.0 (Q3 2025).